Skip to content

Study · Animal study (in vivo) · dog · 1996

5 results

Activation of canine monocytes and polymorphonuclear cells by serum thymic factor (FTS) in vivo.

Kosaka T, Nakada Y, Yukawa M, Awaya A, Onodera T, Kuwabara M, Tanaka S

The Journal of veterinary medical science1 Apr 1996Cited by 2 (Europe PMC)

PMID8741264 (opens in a new tab)DOI10.1292/jvms.58.323 (opens in a new tab)PepBankPUB-08741264
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In dogs, FTS did not affect leukocyte numbers.

    In plain wordsIn dogs, FTS did not change white blood cell numbers.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeLeukocyte number
    Study

    dogn: not reported in source

    canine blood leukocytes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    FTS did not affect the number of leukocytes and differential count of leukocytes.
    1 context sentence
    Summary · context
    The effect of serum thymic factor (FTS) was evaluated from the immunoresponse augmented in canine monocytes and polymorphonuclear cells (PMN) using the chemiluminescence technique.
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In dogs, FTS did not affect differential leukocyte counts.

    In plain wordsIn dogs, FTS did not change the proportions of white blood cell types.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeDifferential leukocyte count
    Study

    dogn: not reported in source

    canine blood leukocytes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    FTS did not affect the number of leukocytes and differential count of leukocytes.
    1 context sentence
    Summary · context
    The effect of serum thymic factor (FTS) was evaluated from the immunoresponse augmented in canine monocytes and polymorphonuclear cells (PMN) using the chemiluminescence technique.
  3. 03AnimalAnimal study (in vivo)Activity measurement

    In dogs, FTS elevated whole-blood chemiluminescence from 72 to 120 hr, with about a 3-fold increase at 96 hr.

    In plain wordsIn dogs, FTS increased whole-blood chemiluminescence compared with levels before treatment.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseWhole-blood chemiluminescence
    Study

    dogn: not reported in source

    canine blood leukocytes
    Comparator
    before FTS administration
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Chemiluminescence fold change
    ≈ 3 fold
    96 hr versus before administration

    Source sentences

    Summary
    CL activity of the whole blood was significantly elevated by FTS from 72 hr to 120 hr after administration (p < 0.05), and that at 96 hr after administration was about 3-fold higher than that before the administration.
    1 context sentence
    Summary · context
    The effect of serum thymic factor (FTS) was evaluated from the immunoresponse augmented in canine monocytes and polymorphonuclear cells (PMN) using the chemiluminescence technique.
  4. 04AnimalAnimal study (in vivo)Activity measurement

    In dogs, FTS elevated polymorphonuclear-cell chemiluminescence from 24 to 96 hr, with about a 7-fold increase at 48 hr.

    In plain wordsIn dogs, FTS increased polymorphonuclear-cell chemiluminescence compared with levels before treatment.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreasePolymorphonuclear-cell chemiluminescence
    Study

    dogn: not reported in source

    canine blood leukocytes
    Comparator
    prior treatment
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Chemiluminescence fold change
    ≈ 7 fold
    48 hr versus prior treatment

    Source sentences

    Summary
    The CL response of PMN was significantly elevated by FTS administration from 24 hr to 96 hr after administration (p < 0.05), and that at 48 hr after administration was about 7-fold higher than prior treatment.
    1 context sentence
    Summary · context
    The effect of serum thymic factor (FTS) was evaluated from the immunoresponse augmented in canine monocytes and polymorphonuclear cells (PMN) using the chemiluminescence technique.
  5. 05AnimalAnimal study (in vivo)Activity measurement

    In dogs, FTS elevated monocyte chemiluminescence from 24 to 96 hr, with about 100-fold higher counts at 24 and 48 hr.

    In plain wordsIn dogs, FTS increased monocyte chemiluminescence compared with levels before treatment.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseMonocyte chemiluminescence
    Study

    dogn: not reported in source

    canine blood leukocytes
    Comparator
    before FTS administration
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Chemiluminescence fold change
    ≈ 100 fold
    24 hr and 48 hr versus before administration

    Source sentences

    Summary
    FTS also significantly elevated the CL response of monocyte from 24 hr to 96 hr after administration (p < 0.01), and the CL count of monocyte in 24 hr and 48 hr was about 100-fold higher than that before FTS administration.
    1 context sentence
    Summary · context
    The effect of serum thymic factor (FTS) was evaluated from the immunoresponse augmented in canine monocytes and polymorphonuclear cells (PMN) using the chemiluminescence technique.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.